HealthcareServices

Congestive Heart Failure (CHF) Industry Poised for Rapid Growth, Forecast to Touch $23.78 Billion by 2030 at 6.8% CAGR

February 23, 2026February 23, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the congestive heart failure (chf) market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Congestive Heart Failure (CHF) Market in 2030?

The market for congestive heart failure (chf) has seen significant expansion in recent years. Looking ahead, its value is expected to increase from $17.1 billion in 2025 to $18.31 billion in 2026, driven by a compound annual growth rate (CAGR) of 7.1%. Historically, this growth can be ascribed to an expanding aging population, the high prevalence of cardiovascular disease, restricted outpatient monitoring options, frequent hospital readmissions, and a reliance on hospital-based care.

The congestive heart failure (CHF) market size is projected to experience robust expansion in the coming years. It is anticipated to reach $23.79 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.8%. This growth during the forecast period stems from factors such as the rising prevalence of heart failure, enhanced diagnostic precision, the expansion of homecare environments, increased uptake of guideline-driven therapies, and an emphasis on decreasing hospital readmissions. Key trends identified for the forecast timeframe encompass the growing embrace of combination drug treatments, a move towards managing heart failure at home, heightened attention to early diagnosis and patient monitoring, an increase in chronic disease management initiatives, and the broadening of post-discharge care routes.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20730&type=smp

What Drivers Are Influencing Production Trends In The Congestive Heart Failure (CHF) Market?

The expanding number of individuals suffering from cardiovascular conditions is anticipated to fuel the expansion of the congestive heart failure (CHF) market in the coming period. Cardiovascular pertains to the heart and blood vessels, with its primary function being the circulation of blood and the preservation of the body’s general well-being. This surge in cardiovascular patient numbers is attributed to inactive lifestyles, poor dietary habits, an aging demographic, and increasing urbanization, consequently increasing the demand for sophisticated healthcare and therapeutic interventions. Congestive heart failure (CHF) offerings are beneficial for cardiovascular patients as they deliver specific remedies that boost cardiac function, alleviate symptoms, and avert complications, thereby improving patient care and their overall quality of life. To illustrate, in January 2023, data from the American College of Cardiology, a US-based nonprofit medical society, indicated that cardiovascular disease instances climbed to 19.8 million in 2022. Furthermore, Eastern Europe records the highest death rate, standing at 553 deaths per 100,000. Consequently, the growing population of cardiovascular patients is propelling the development within the congestive heart failure (CHF) market.

Which Segment Groups Are Influencing The Congestive Heart Failure (CHF) Market?

The congestive heart failure (chf) market covered in this report is segmented –

1) By Type: Systolic Heart Failure, Diastolic Heart Failure, Left-Sided Heart Failure, Right-Sided Heart Failure

2) By Treatment: Medication, Surgery

3) By Diagnosis: Electrocardiogram, Echocardiogram, Magnetic Resonance Imaging (MRI), Stress Test, Blood Tests, Cardiac Catheterization, Other Diagnosis

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Homecare Settings

Subsegments:

1) By Systolic Heart Failure: Reduced Ejection Fraction (HFrEF), Mild-to-moderate Reduced Ejection Fraction

2) By Diastolic Heart Failure: Preserved Ejection Fraction (HFpEF), Borderline Ejection Fraction (HFpEF)

3) By Left-Sided Heart Failure: Acute Left-Sided Heart Failure, Chronic Left-Sided Heart Failure

4) By Right-Sided Heart Failure: Acute Right-Sided Heart Failure, Chronic Right-Sided Heart Failure

What Upcoming Trends Are Likely To Define The Future Path Of The Congestive Heart Failure (CHF) Market?

Leading firms in the congestive heart failure (CHF) market are prioritizing cutting-edge innovations, including single intracoronary infusion therapies, to provide impactful treatment choices that enhance cardiac function and improve the well-being of CHF patients. This technique, single intracoronary infusion, involves administering medication straight into the coronary artery, directly addressing the heart for accurate treatment of conditions such as congestive heart failure (CHF). As an example, in January 2024, Bayer AG, a pharmaceutical company based in Germany, along with Asklepios Biopharmaceutical, Inc., a US biotechnology firm, commenced the GenePHIT Phase II trial for AB-1002, an experimental gene therapy designed for congestive heart failure (CHF). This particular innovation employs a gene therapy methodology to address non-ischemic cardiomyopathy, potentially presenting a significant advancement in CHF treatment via sophisticated genetic methods. The trial structure is adaptive, double-blind, and placebo-controlled, planning to recruit between 90 and 150 participants who have maintained medical stability for a minimum of four weeks and exhibit a left ventricular ejection fraction between 15% and 35%.

Who Are The Primary Competitors In The Global Congestive Heart Failure (CHF) Market?

Major companies operating in the congestive heart failure (chf) market are Pfizer Inc., Johnson & Johnson Inc., Boehringer Ingelheim International GmbH, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol‑Myers Squibb Company, Abbott Laboratories, Novartis AG, Medtronic Plc, Canon Medical Systems Corporation, Jarvik Heart Inc., Boston Scientific Corporation, Biotronik SE & Co. KG, LivaNova Plc, Edwards Lifesciences Corporation, Getinge AB, MicroPort Scientific Corporation, Lepu Medical Technology Co Ltd, OSCOR Inc., Shree Pacetronix Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/congestive-heart-failure-chf-global-market-report

Which Regions Are Projected To Dominate The Congestive Heart Failure (CHF) Market In The Coming Years?

North America was the largest region in the congestive heart failure (CHF) market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the congestive heart failure (chf) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Congestive Heart Failure (CHF) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20730&type=smp

Browse Through More Reports Similar to the Global Congestive Heart Failure (CHF) Market 2026, By The Business Research Company

Structural Heart Market Report 2026

https://www.thebusinessresearchcompany.com/report/structural-heart-global-market-report

Congestive Heart Failure Treatment Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/congestive-heart-failure-treatment-devices-global-market-report

Congenital Heart Disease Chd Market Report 2026

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795